Wieneke H, Otte B, Lang D, Heidenreich S
Department of Medicine, University of Münster, Germany.
Clin Nephrol. 1996 Jan;45(1):22-8.
Renal allograft recipients are at risk to acquire infectious disease complications primarily after an intensified immunosuppressive therapy. In this study, serum levels of IgG, IgA, IgM and IgG subclasses were compared between transplant patients after different anti-rejection regimen and evaluated as possible predictive markers for infectious implications. Thirty-six renal transplant recipients in the early posttransplantation period were allocated into three subgroups: group 1 consisted of 15 subjects with good primary graft function standing under a basal triple drug immunosuppression; patients of group 2 (n = 9) had a very early acute rejection episode which was treated by high steroid doses and patients of group 3 (n = 12) required antithymocyte globulin (ATG) therapy for acute rejection. Immune parameters were studied 5 weeks after transplantation, when basal triple drug immunosuppression was continued in all patients. Twenty-three age-matched patients under chronic hemodialysis were recruited as a control group. Total IgG serum levels were reduced in transplant patients compared to dialysis subjects, whereas IgA and IgM levels were not altered. IgG subclass analysis revealed, that IgG1 levels were similar in stable transplant compared to chronic hemodialysis patients, but were significantly reduced in rejection patients after steroid pulses or ATG therapy. IgG3 levels were significantly reduced in all transplant recipients compared to dialysis patients without differences between the transplant subgroups. IgG2 and IgG4 subclass levels were similar in all studied subjects. IgG subclass abnormalities were paralleled by a reduction of lymphocyte subsets in rejection patients of groups 2 and 3, which may be the basis for an altered Ig class switching. Seven out of 36 studied transplant patients had severe infections in the early posttransplantation period with four cases of viral infections. Patients with infections had significantly lower IgG1 levels and CD4 positive lymphocyte numbers but similar total IgG levels compared to patients without infections. So IgG1 levels may be of value to predict the occurrence of infectious complications in renal allograft recipients in the early posttransplantation period.
肾移植受者主要在强化免疫抑制治疗后有发生感染性疾病并发症的风险。在本研究中,比较了不同抗排斥方案后的移植患者血清中IgG、IgA、IgM和IgG亚类水平,并将其评估为感染相关的可能预测标志物。36例移植后早期的肾移植受者被分为三个亚组:第1组由15例在基础三联药物免疫抑制下移植肾功能良好的受试者组成;第2组(n = 9)的患者发生了非常早期的急性排斥反应,接受了高剂量类固醇治疗,第3组(n = 12)的患者因急性排斥反应需要抗胸腺细胞球蛋白(ATG)治疗。在移植后5周研究免疫参数,此时所有患者均继续接受基础三联药物免疫抑制。招募了23例年龄匹配的慢性血液透析患者作为对照组。与透析受试者相比,移植患者的总IgG血清水平降低,而IgA和IgM水平未改变。IgG亚类分析显示,稳定移植患者的IgG1水平与慢性血液透析患者相似,但在接受类固醇冲击或ATG治疗后的排斥患者中显著降低。与透析患者相比,所有移植受者的IgG3水平均显著降低,移植亚组之间无差异。所有研究对象的IgG2和IgG4亚类水平相似。第2组和第3组排斥患者的淋巴细胞亚群减少与IgG亚类异常平行,这可能是Ig类转换改变的基础。在36例研究的移植患者中,有7例在移植后早期发生了严重感染,其中4例为病毒感染。与未感染患者相比,感染患者的IgG1水平和CD4阳性淋巴细胞数量显著降低,但总IgG水平相似。因此,IgG1水平可能对预测肾移植受者移植后早期感染并发症的发生有价值。